首页> 外国专利> New triterpenic alkaloids useful as a medicament to treat e.g. central nervous system and peripheral disorders

New triterpenic alkaloids useful as a medicament to treat e.g. central nervous system and peripheral disorders

机译:新的三萜生物碱可用作药物治疗例如中枢神经系统和周围疾病

摘要

Triterpenic alkaloids (I) and their addition salts, isomers, enantiomers and/or diastereomers are new. Triterpenic alkaloids of formula (I) and their addition salts, isomers, enantiomers and/or diastereomers are new. R 1-CH 2X 1R 7, -CH=NR 5or -CH=O; X 1-X 3O, NH or S; R 7, R 8H, 1-10C alkyl, 1-10C alkyl-phenyl, 1-10C alkyl-carbonyl or SO 2R 9; R 91-10C alkyl or 1-10C alkyl-phenyl; either R ,R 3H or -C(=X)-R 10; or R 10H, 1-10C alkyl, (1-10C alkyl)phenyl, 3-10C cycloalkyl; R 4H, 10C alkyl or -X 3-R 12; R 12H (preferred), 1-10C alkylcarbonyl, 1-10C alkyl-phenyl or 1-10C alkyl-sulfonyl; R 5N-oxide-N +OCH 3R 13or NCH 3R 13; R 13H, 3-10C cycloalkyl, 1-10C alkyl, phenyl or phthalimide (preferably CH 3); R 6=O or -OR 14; and R 14H, 1-10C alkyl, 1-10C alkylcarbonyl, 1-10C alkyl-phenyl or 1-10C alkyl-sulfonyl. Provided that: when X 1is S, R 7is not SO 2R 9; at least one of R 2and R 3is H. Provided that: when R 2is absent, then R 1is -CH 2X 1R 7, and NR 7and X 1R 7together forms -N=C(R 11)-X 1- (where R 11is H, 1= 1-C alkyl, (1-C alkyl)phenyl) or 3-10C cycloalkyl); when R 2= H, then R 1is -CH 2X 1R 7, and NR 7and X 1R 7together forms -N-CH(R 11)-X 1-. Provided that (I) is not: N-(16-Hydroxy-4-hydroxymethyl-17-isopropyl-4,13,14-trimethyl-11-oxo-tetradecahydro-cyclopropa[9,10]cyclopenta[a]phenanthren-3-yl)-isobutyramide; N-[3-(1-dimethylamino-ethyl)-2-hydroxy-10-hydroxymethyl-3a,10,12b-trimethyl-5-oxo-1,2,3,3a,4,5,5a,6,8,9,10,10a,11,12,12a,12b-hexadecahydro-benzo[4,5]cyclohepta[1,2-e]inden-9-yl]-isobutyramide; N-[17-(1-dimethylamino-ethyl)-16-hydroxy-4-hydroxymethyl-4,13,14-trimethyl-11-oxo-tetradecahydro-cyclopropa[9,10]cyclopenta[a]phenanthren-3-yl]-benzamide; acetic acid 4-acetoxymethyl-17-(1-dimethylamino-ethyl)-3-isobutyrylamino-4,13,14-trimethyl-11-oxo-tetradecahydro-cyclopropa[9,10]cyclopenta[a]phenanthren-16-yl ester; 3-(1-dimethylamino-ethyl)-2-hydroxy-10-isopropyl-3a,12a,14b-trimethyl-2,3,3a,5a,6,8,8a,12,12a,12b,13,14,14a,14b-tetradecahydro-1H,4H-11-oxa-9-aza-indeno[5',4':4,5]cyclohepta[1,2-a]naphthalen-5-one; acetic acid 3-(1-dimethylamino-ethyl)-10-isopropyl-3a,12a,14b-trimethyl-5-oxo-2,3,3a,4,5,5a,6,8,8a,12,12a,12b,13,14,14a,14b-hexadecahydro-1H-11-oxa-9-aza-indeno[5',4':4,5]cyclohepta[1,2-a]naphthalen-2-yl ester, 3-(1-dimethylamino-ethyl)-2-hydroxy-10-isopropyl-3a,12a,14b-trimethyl-2,3,3a,5a,6,8,8a,9,10,12,12a,12b,13,14,14a,14b-hexadecahydro-1H,4H-11-oxa-9-aza-indeno[5',4':4,5]cyclohepta[1,2-a]naphthalen-5-one; N-[3-(1-dimethylamino-ethyl)-2-hydroxy-10-hydroxymethyl-3a,10,12b-trimethyl-5-oxo-1,2,3,3a,4,5,6a,7,8,9,10,10a,11,12,12a,12b-hexadecahydro-benzo[4,5]cyclohepta[1,2-e]inden-9-yl]-isobutyramide; N-[16-hydroxy-4-hydroxymethyl-4,13,14-trimethyl-17-(1-methylamino-ethyl)-11-oxo-tetradecahydro-cyclopropa[9,10]cyclopenta[a]phenanthren-3-yl]-isobutyramide; methanesulfonic acid 17-(1-dimethylamino-ethyl)-3-isobutyrylamino-16-methanesulfonyloxy-4,13,14-trimethyl-11-oxo-tetradecahydro-cyclopropa[9,10]cyclopenta[a]phenanthren-4-ylmethyl ester; acetic acid 16-acetoxy-17-[1-(acetyl-methyl-amino)-ethyl]-3-isobutyrylamino-4,13,14-trimethyl-11-oxo-tetradecahydro-cyclopropa[9,10]cyclopenta[a]phenanthren-4-ylmethyl ester or alkaloid compound of formula (Ic), where all the above compounds are in their stereo isomeric form. Independent claims are included for: (1) the preparations of (I); and (2) the preparation of intermediate N-(16-hydroxy-4-hydroxymethyl-17-isopropyl-4,13,14-trimethyl-11-oxo-tetradecahydro-cyclopropa[9,10]cyclopenta[a]phenanthren-3-yl)-isobutyramide of formula (X). [Image] [Image] [Image] ACTIVITY : CNS-Gen.; Neuroprotective; Nootropic; Antiparkinsonian; Vasotropic; Tranquilizer; Vulnerary; Muscular-Gen. MECHANISM OF ACTION : Acetylcholinesterase inhibitor. The ability of (I) to inhibit acetylcholinesterase was tested using in vitro assay in human. The results showed (20S)-3beta -isobutyrylamino-9,19-cyclo-4alpha -hydroxymethyl-4beta ,14alpha -dimethyl-20-dimethylamino-5alpha ,9beta -pregnan-16alpha -ol-11-one exhibited IC 50value of 31 nM.
机译:三萜生物碱(I)及其加成盐,异构体,对映异构体和/或非对映异构体是新的。式(I)的三萜生物碱及其加成盐,异构体,对映异构体和/或非对映异构体是新的。 R 1-CH 2X 1R 7,-CH = NR 5或-CH = O; X 1-X 3O,NH或S; R 7,R 8H,1-10C烷基,1-10C烷基-苯基,1-10C烷基-羰基或SO 2R 9; R 91-10C烷基或1-10C烷基-苯基; R 3R或-C(= X)-R 10; R 10H,1-10C烷基,(1-10C烷基)苯基,3-10C环烷基; R 4H,10 C烷基或-X 3-R 12; R 12H(优选),1-10C烷基羰基,1-10C烷基苯基或1-10C烷基磺酰基; R 5N-氧化物-N +> OCH 3R 13或NCH 3R 13; R 13H,3-10C环烷基,1-10C烷基,苯基或邻苯二甲酰亚胺(最好是CH 3); R 6 = O或-OR 14; R 14H,1-10C烷基,1-10C烷基羰基,1-10C烷基-苯基或1-10C烷基-磺酰基。规定:当X 1为S时,R 7不为SO 2R 9; R 2和R 3的至少一个是H。前提是:当R 2不存在时,R 1是-CH 2X 1R 7和NR 7和X 1R 7一起形成-N = C(R 11)-X 1-(其中R 11是H,1 = 1-C烷基,(1-C烷基)苯基)或3-10C环烷基);当R 2 = H时,R 1为-CH 2X 1R 7,并且NR 7和X 1R 7一起形成-N-CH(R 11)-X 1-。前提是(I)不是:N-(16-羟基-4-羟甲基-17-异丙基-4,13,14-三甲基-11-氧代-十四氢-环丙烷[9,10]环戊[a]菲蒽-3 -yl)-异丁酰胺; N- [3-(1-二甲基氨基-乙基)-2-羟基-10-羟甲基-3a,10,12b-三甲基-5-氧代-1,2,3,3a,4,5,5a,6,8 ,9,10,10a,11,12,12a,12b-十六氢-苯并[4,5]环庚[1,2-e]茚满-9-基]-异丁酰胺; N- [17-(1-二甲基氨基-乙基)-16-羟基-4-羟基甲基-4,13,14-三甲基-11-氧代-十四氢-环丙烷[9,10]环戊[a]菲蒽-3-基]-苯甲酰胺;乙酸4-乙酰氧基甲基-17-(1-二甲基氨基-乙基)-3-异丁酰基氨基-4,13,14-三甲基-11-氧代-十四氢-环丙烷[9,10]环戊[a]菲蒽-16-基酯; 3-(1-二甲基氨基-乙基)-2-羟基-10-异丙基-3a,12a,14b-三甲基-2,3,3a,5a,6,8,8a,12,12a,12b,13,14, 14a,14b-十四氢-1H,4H-11-oxa-9-氮杂-茚并[5',4':4,5]环庚[1,2-a]萘-5-酮;乙酸3-(1-二甲基氨基-乙基)-10-异丙基-3a,12a,14b-三甲基-5-氧代-2,3,3a,4,5,5a,6,8,8a,12,12a, 12b,13,14,14a,14b-十六氢-1H-11-oxa-9-氮杂-茚并[5',4':4,5]环庚[1,2-a]萘-2-基酯,3 -(1-二甲基氨基-乙基)-2-羟基-10-异丙基-3a,12a,14b-三甲基-2,3,3a,5a,6,8,8a,9,10,12,12a,12b,13 ,14,14a,14b-十六氢-1H,4H-11-oxa-9-氮杂-茚并[5',4':4,5]环庚[1,2-a]萘-5-酮; N- [3-(1-二甲基氨基-乙基)-2-羟基-10-羟甲基-3a,10,12b-三甲基-5-氧代-1,2,3,3a,4,5,6a,7,8 ,9,10,10a,11,12,12a,12b-十六氢-苯并[4,5]环庚[1,2-e]茚满-9-基]-异丁酰胺; N- [16-羟基-4-羟基甲基-4,13,14-三甲基-17-(1-甲基氨基-乙基)-11-氧-十四氢-环丙烷[9,10]环戊[a]菲蒽-3-基]-异丁酰胺;甲磺酸17-(1-二甲基氨基-乙基)-3-异丁酰基氨基-16-甲磺酰氧基-4,13,14-三甲基-11-氧代-十四氢-环丙烷[9,10]环戊[a]菲蒽-4-基甲基酯;乙酸16-乙酰氧基-17- [1-(乙酰甲基甲基氨基)-乙基] -3-异丁酰基氨基-4,13,14-三甲基-11-氧代-十四氢-环丙烷[9,10]环戊[a]式(Ic)的菲蒽-4-基甲基酯或生物碱化合物,其中所有上述化合物均为其立体异构体形式。独立索赔包括:(1)(I)的制剂; (2)制备中间体N-(16-羟基-4-羟甲基-17-异丙基-4,13,14-三甲基-11-氧代-十四氢-环丙烷[9,10]环戊[a]菲蒽-3式(X)的-基)-异丁酰胺。 [图片] [图片] [图片]活动:CNS-Gen .;具有神经保护作用;促智;反帕金森病;变压性镇静剂;伤药;肌肉一代。作用机理:乙酰胆碱酯酶抑制剂。 (I)抑制乙酰胆碱酯酶的能力是通过在人体内的体外试验来测试的。结果显示(20S)-3beta -isobutyrylamino-9,19-cyclo-4alpha -hydroxymethyl-4beta,14alpha -dimethyl-20-dimethylamino-5alpha,9beta -pregnan-16alpha -ol-11-one的IC 50值为31 nM 。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号